Event Calendar

October 2017?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. Please select a highlighted date from the calendar to see date-specific company information, including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
12345
Oct 5, 2017
SC 13D
Formats:  Excel HTML Adobe PDF Word
6
Oct 6, 2017
SC 13G
Formats:  Excel HTML Adobe PDF Word
7
891011121314
15161718192021
22232425262728
29303151525354
Calendar Instructions
Please select a highlighted date from the calendar to view company related information. This calendar requires JavaScript to be installed and activated on your browser.
Upcoming Events
There are currently no events scheduled.
Past Events
DateTitle
09/13/17 8:30 a.m. ET
Inotek Pharmaceuticals and Rocket Pharmaceuticals Joint Conference Call
Description:

US Playback: (855) 859-2056
International Playback: (404) 537-3406
Conference ID: 85020110

IMPORTANT ADDITIONAL INFORMATION TO BE FILED WITH THE SEC
This communication is being made in connection with the proposed merger transaction involving Inotek Pharmaceuticals Corporation (Inotek) and Rocket Pharmaceuticals, Ltd. (Rocket).  In connection with the proposed transaction, Inotek plans to file with the Securities and Exchange Commission (SEC) a proxy statement relating to the approval of the merger agreement. The information in the preliminary proxy statement is not complete and may be changed. The proxy statement, press release announcing the proposed transaction and conference call on the proposed transaction, and related presentation, are not offers to sell Inotek securities and are not soliciting an offer to buy Inotek securities in any state where the offer and sale is not permitted.

The definitive proxy statement will be mailed to stockholders of Inotek. INOTEK URGES INVESTORS AND SECURITY HOLDERS TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the definitive proxy statement (when available) and other documents filed with the SEC by Inotek through the web site maintained by the SEC at www.sec.gov. Free copies of the definitive proxy statement (when available) and other documents filed with the SEC can also be obtained on Inotek’s website at http://ir.inotekpharma.com/phoenix.zhtml?c=254118&p=irol-sec.

Participants in Solicitation
Inotek, Rocket and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Inotek in connection with the merger. Information about the directors and executive officers of Inotek is set forth in Inotek’s Form 10-K for the fiscal year ended December 31, 2016 and filed with the SEC on March 16, 2017 and the proxy statement filed with the SEC on April 26, 2017. Additional information regarding the interests of these participants and other persons who may be deemed participants in the merger may be obtained by reading the proxy statement regarding the proposed transaction when it becomes available.

This document will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.  

Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These statements, as they relate to Inotek or Rocket, the management of either such company or the proposed transaction between Inotek and Rocket, involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These statements are based on current plans, estimates and projections, and therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Inotek and Rocket undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and future financial results of the pharmaceutical industry, and other legal, regulatory and economic developments. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including, but not limited to, those described in the documents Inotek has filed with the SEC as well as the possibility that (1) the parties may be unable to obtain stockholder or regulatory approvals required for the proposed transaction or may be required to accept conditions that could reduce the anticipated benefits of the merger as a condition to obtaining regulatory approvals; (2) the length of time necessary to consummate the proposed transaction may be longer than anticipated; (3) the parties may not be able to satisfy the conditions precedent to consummate the proposed transaction; (4) the proposed transaction may divert management’s attention from Inotek’s ongoing business operations; (5) the anticipated benefits of the proposed transaction might not be achieved; (6) Rocket’s clinical programs and pre-clinical studies may not be successful or completed on time;  (7) Rocket may not be able to successfully demonstrate safety and efficacy of its clinical programs or pre-clinical studies; (8) Rocket’s expectations regarding the future development of its clinical programs and pre-clinical studies may not materialize; (9) Rocket’s clinical programs may not obtain necessary regulatory or other approvals; (10) Rocket’s clinical programs may not meet proof of concept; (11) Rocket may not be able to raise the necessary capital to conduct Rocket’s clinical programs and pre-clinical studies or such capital may not be available; (12) the prospective market size of Rocket’s drug candidates may be different than currently anticipated; (13) the proposed transaction may involve unexpected costs; (14) the business may suffer as a result of uncertainty surrounding the proposed transaction, including difficulties in maintaining relationships with third parties or retaining key employees; (15) the parties may be unable to meet expectations regarding the timing, completion and accounting and tax treatments of the transaction; (16) the parties may be subject to risks related to the proposed transaction, including any legal proceedings related to the proposed transaction and the general risks associated with the respective businesses of Inotek and Rocket, including the general volatility of the capital markets, terms and deployment of capital, volatility of Inotek share prices, changes in the biotechnology industry, interest rates or the general economy, underperformance of Inotek’s or Rocket’s assets and investments, decreased ability to raise funds and the degree and nature of Inotek’s and Rocket’s competition, as well as the risk that unexpected reductions in Inotek’s cash balance could adversely affect the portion of the combined company that the Inotek stockholders retain; (17) activist investors might not approve of the proposed transaction; or (18) the risks that are more fully described in the section titled “Risk Factors” in Inotek’s most recent Quarterly Report on Form 10-Q filed with the SEC, as well as subsequent and other documents filed from time to time with the SEC by Inotek could materialize. Additionally, forward-looking statements related to Rocket’s future expectations are subject to numerous risks and uncertainties, including risks that planned development milestones and timelines will not be met. Additional risks relating to Rocket’s business and operations will be set forth in the proxy statement that Inotek will file to seek stockholder approval of the merger. Neither Inotek nor Rocket gives any assurance that either Inotek or Rocket will achieve its expectations. 

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Inotek described in the “Risk Factors” section of its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed by Inotek from time to time with the SEC, as well as Risk Factors relating to Rocket that will be contained in definitive proxy statement for the proposed merger between Inotek and Rocket. All forward-looking statements included in this document are based upon information available to Inotek and Rocket the date hereof, and neither Inotek nor Rocket assumes any obligation to update or revise any such forward-looking statements.

Supporting 
Materials: 
Download Event Supporting Material  Inotek Pharmaceuticals and Rocket Pharmaceuticals Joint Conference Presentation
07/10/17 8:30 a.m. ET
Inotek Pharmaceuticals FDC Top-line Results and Corporate Update Conference Call
03/13/17 4:30 p.m. PT
29th Annual ROTH Conference
Location: Dana Point, CA
03/06/17 4:00 p.m. ET
Cowen and Company 37th Annual Health Care Conference
Location: Boston, MA
02/14/17 1:00 p.m. ET
BIO CEO and Investor Conference
01/03/17 8:30 a.m. ET
Inotek Pharmaceuticals Top-line MATrX-1 Results Conference Call
Supporting 
Materials: 
Download Event Supporting Material Inotek Announces Top-line MATrX-1 Results Presentation
11/29/16 12:30 p.m. ET
Piper Jaffray 28th Annual Healthcare Conference
11/16/16 10:15 a.m. ET
Stifel 2016 Healthcare Conference
11/14/16
Global Mizuho Investor Conference
10/15/16
American Academy of Ophthalmology 2016 Annual Meeting
Location: Chicago, IL
09/21/16
Mizuho Securities Therapeutics Conference
09/13/16
Rodman & Renshaw 18th Annual Global Investment Conference
08/10/16 10:00 a.m. ET
Canaccord Genuity: 36th Annual Growth Conference
Location: Boston, MA
07/12/16 1:30 p.m. ET
Cantor Fitzgerald 2nd Annual Healthcare Conference
Location: New York, NY
Supporting 
Materials: 
Download Event Supporting Material Corporate Presentation July 2016
03/07/16 2:00 p.m. ET
Cowen and Company 36th Annual Health Care Conference
02/08/16 9:30 a.m. ET
18th Annual BIO CEO & Investor Conference
Location: Waldorf Astoria Hotel
New York, NY
12/17/15 10:00 a.m. ET
Inotek Pharmaceuticals Corporation R&D Day
Description: Dial Information: Domestic: 1 (866) 430-2017
International: 1 (704) 908-0413
Password: 90883071
Location: New York, NY
11/12/15 11:09 a.m. PT
Inotek Pharmaceuticals Corporation at the 2015 Ophthalmology Innovation Summit
07/23/15 8:30 a.m. ET
Inotek Pharmaceuticals Corporation - Phase 3 Development Plan Conference Call